These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37896812)

  • 21. Use of anakinra in severe COVID-19: A case report.
    Filocamo G; Mangioni D; Tagliabue P; Aliberti S; Costantino G; Minoia F; Bandera A
    Int J Infect Dis; 2020 Jul; 96():607-609. PubMed ID: 32437934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
    de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
    Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.
    Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V
    Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.
    Dahms K; Mikolajewska A; Ansems K; Metzendorf MI; Benstoem C; Stegemann M
    Eur J Med Res; 2023 Feb; 28(1):100. PubMed ID: 36841793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current evidence on the use of anakinra in COVID-19.
    Khani E; Shahrabi M; Rezaei H; Pourkarim F; Afsharirad H; Solduzian M
    Int Immunopharmacol; 2022 Oct; 111():109075. PubMed ID: 35905562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study.
    Balkhair A; Al-Zakwani I; Al Busaidi M; Al-Khirbash A; Al Mubaihsi S; BaTaher H; Al Aghbari J; Al Busaidi I; Al Kindi M; Baawain S; Al Alawi A; Al Lawati A; Al Rawahi B; Al-Baimani K; Al Zidi K; Elfatih N; Dawud B; John B; Rehman F; Yousif F; Al Khadouri G; Saber I; Lal J; Gargouri M; Al-Ward M; AbuDraz N; Al Ruqeishi S; Kumar S; Abdelmottaleb W; Al-Naamani Z; Bin Nazar Z; Balkhair O
    Int J Infect Dis; 2021 Feb; 103():288-296. PubMed ID: 33217576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center.
    Bektaş M; Yüce S; Ay M; Uyar MH; Önder ME; Kılıç Mİ
    Inflammopharmacology; 2023 Apr; 31(2):787-797. PubMed ID: 36707494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.
    Kharazmi AB; Moradi O; Haghighi M; Kouchek M; Manafi-Rasi A; Raoufi M; Shoaei SD; Hadavand F; Nabavi M; Miri MM; Salarian S; Shojaei S; Khalili S; Sistanizad M; Sadeghi S; Karagah A; Asgari S; Jaffaraghaei M; Araghi S
    Immun Inflamm Dis; 2022 Feb; 10(2):201-208. PubMed ID: 34762351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of anakinra compared to standard care of treatment for COVID-19: a meta-analysis.
    Malık H; Bınt Abdul Jabbar H; Latıf F; Sarfraz A; Sarfraz Z; Sarfraz M
    Turk J Med Sci; 2022 Jun; 52(3):547-553. PubMed ID: 36326309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
    Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
    Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
    Kooistra EJ; Waalders NJB; Grondman I; Janssen NAF; de Nooijer AH; Netea MG; van de Veerdonk FL; Ewalds E; van der Hoeven JG; Kox M; Pickkers P;
    Crit Care; 2020 Dec; 24(1):688. PubMed ID: 33302991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
    Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
    Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).
    Ghofrani Nezhad M; Jami G; Kooshkaki O; Chamani S; Naghizadeh A
    J Interferon Cytokine Res; 2023 Apr; 43(4):147-163. PubMed ID: 37062817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lescure FX; Honda H; Fowler RA; Lazar JS; Shi G; Wung P; Patel N; Hagino O;
    Lancet Respir Med; 2021 May; 9(5):522-532. PubMed ID: 33676590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness.
    Langer-Gould A; Xu S; Myers LC; Chen A; Greene JD; Creekmur B; Bruxvoort K; Adams JL; Liu V; Gould MK
    Int J Infect Dis; 2023 Jan; 126():87-93. PubMed ID: 36403818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.